关键数据
1.050今开
1.075最高
478.64K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.45%换手率
1.050昨收
1.005最低
297.56K成交额
亏损市盈率静
0.65市净率
0.00%股息率 TTM
-18.43%ROA
2.40052周最高
0.53量比
-41.05M净利润
106.79M总股本
-0.3669每股收益TTM
1.45Beta
-21.30%ROE
0.64352周最低
6.67%振幅
73.22%毛利率
112.13M总市值
-4.16回报/风险
4.17%风险率
操作建议
MaxCyte Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名70/199位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价4.11。中期看,股价处于上升通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
MaxCyte Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Edwards Lifesciences Corp
EW
33
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
MaxCyte Inc简介
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
公司代码MXCT
公司MaxCyte Inc
CEOMasoud (Maher)
网址https://www.maxcyte.com/
公司股东
常见问题
MaxCyte Inc(MXCT)的当前股价是多少?
MaxCyte Inc(MXCT)的当前股价是 1.05。
MaxCyte Inc股票的52周最高点是多少?
MaxCyte Inc股票的52周最高点是2.40。
MaxCyte Inc股票的52周最低点是多少?
MaxCyte Inc股票的52周最低点是0.64。
现在MaxCyte Inc(MXCT)的股票是买入、持有还是卖出?
根据分析师评级,MaxCyte Inc(MXCT)的总体评级为买入,目标价格为4.11。
MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是多少
MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是-0.42。